Artificial Cell Technologies (ACT) is a pioneering biotechnology company based in New Haven, CT, that is revolutionizing the production of vaccines through their patented technology platform. By utilizing ultra-thin multilayer polypeptide nanofilms, ACT is able to produce rapid, synthetic vaccines that are not only personalized but can also be manufactured on-demand, significantly changing the market and potentially saving lives.
With a focus on developing vaccines for infectious diseases in the developing world, ACT aims to overcome the limitations of traditional vaccine manufacturing by decentralizing the process and creating temperature-stable vaccines that can be administered without the need for medically trained staff. Their first two vaccines, targeting malaria and Respiratory Syncytial Virus (RSV), are currently in pre-clinical development and hold the promise of reaching more people in less time and at a fraction of the cost compared to conventional vaccines.
Generated from the website